Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
about
Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide ImagesAlgorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.Multigene prognostic tests in breast cancer: past, present, futureImpact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.Gene-Expression-Based Predictors for Breast Cancer.Biomarker assessment and molecular testing for prognostication in breast cancer.The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.Risk stratification of prostate cancer 2016.MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.Estimating the OncotypeDX score: validation of an inexpensive estimation tool.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in TurkeyMultiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?Precision oncology in breast cancer: better than ever, or less than before?Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!Magee equations and oncotype DX®-a perspective.21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models.Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients.Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.Luminal A Breast Cancer and Molecular Assays: A Review
P2860
Q28596214-C779FCA2-3046-494D-B1FC-1E049D713442Q31153510-7AB037DB-2D33-4C63-AA0B-67308EDA7692Q31167768-526C0364-5AAA-4B97-8536-7C1DDAE440DFQ33756398-B878C630-95B7-45B7-9452-F6900CBBB704Q35018599-59A77C24-932D-4697-B8AC-F633065E5086Q36791866-70CF01FF-EFD2-43F6-A8EB-CE689817698DQ36842986-8FD07CF7-8AF4-4F5F-B1CD-B33A3E58B2D5Q37488438-A8B023D8-F661-4B5F-9FB8-4A22C558EE52Q37648136-D0E098AC-0696-42BD-9035-3EBB22E31BD2Q38272730-29D18328-C474-4463-9B5D-02F12F4DD121Q38414263-C238D6BC-CBF2-49E7-92F5-0B8FF577A22CQ38555220-54E764E6-47DC-40A9-BD09-819D46AD7BA2Q38696790-BE97013D-918A-4F42-8C06-D4DCA955D48DQ38747402-755B95AC-A1CE-4882-B702-18321F831BF0Q38761797-B894098C-7030-4518-BBB1-5261562E7F28Q38929868-B01DBAE3-547F-4892-93B6-B42A1AE05A2FQ39022633-98A0F01B-AD00-4CE8-B9A6-FEDD1BB99630Q39121120-A5114C52-759E-4FA0-BD24-147FA41A56A3Q39187437-0788A107-671F-46BC-812F-D96C66B47040Q40064664-DE33898E-7CA6-47C3-B3D1-FFCBBC3F6F3EQ40910377-D409A0A8-EB80-4850-94CF-BD4DFECD9B1CQ41823897-BD944287-4982-4A67-864A-8A8C291D3A68Q42353297-A13B109F-A1A3-4CF5-BCF1-F8A6FF7B0974Q45221111-CDF9A4F1-2EFC-4971-A50E-D92919C01ABFQ46383705-37B64AD4-DB69-4911-B11F-F1A0488F97FEQ47109138-2ADF9C5A-105D-491A-89F2-AED3C2A939CAQ47205521-9144D9D0-B6A3-4440-96FE-A2DC95EAA9EDQ47690008-5B478AD3-4200-4B9C-AB24-0B888FFFA24EQ47869675-E66B5A4A-948E-4DBB-8B41-C93AE6AC90DDQ47887164-D091C2C5-66A1-4273-A156-D0889F361F28Q47893249-D23F9465-F2FE-42DD-94C9-133FB0784185Q47918429-F7470392-7DC5-4E21-83A0-C7A76AD3BF38Q48136899-5F1F31CC-407F-4761-BD19-9874007387CEQ48270057-B05E0F0B-3942-4543-8864-12602591F46BQ50089374-EADE9DA7-1B70-4DA0-B7C8-5195AEA8562FQ50921836-C29CEAC2-F4BF-4309-B7B6-6CBCAB1A7F07Q52936770-831017C2-E1A9-4BCA-93CD-5F3A4FD024E6Q54406020-83FE8D13-B720-406D-A408-46C7FAE65DE0Q55182367-8605A98A-B5A0-42EA-9C1B-7C0813A946A2Q57113322-CF861029-77C0-45B8-9A8C-F283544989AC
P2860
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prediction of the Oncotype DX ...... by linear regression analysis.
@en
type
label
Prediction of the Oncotype DX ...... by linear regression analysis.
@en
prefLabel
Prediction of the Oncotype DX ...... by linear regression analysis.
@en
P2093
P2860
P1433
P1476
Prediction of the Oncotype DX ...... by linear regression analysis.
@en
P2093
Adam M Brufsky
David J Dabbs
Molly E Klein
Rachel Jankowitz
Rohit Bhargava
Shannon L Puhalla
Yongli Shuai
P2860
P2888
P304
P356
10.1038/MODPATHOL.2013.36
P577
2013-03-15T00:00:00Z
P5875
P6179
1041911179